Evidence map›Paper›PMID 24722774›Full record

Trial reportPloS one2014

Hip structural parameters over 96 weeks in HIV-infected adults switching treatment to tenofovir-emtricitabine or abacavir-lamivudine.

Hila Haskelberg, Nicholas Pocock, Janaki Amin, Peter Robert Ebeling, Sean Emery, Andrew Carr, STEAL study investigators, Anthony Allworth

Registry-linked trialOpen access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00192634 (A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00192634 phase4completednot on this map

A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study.

TypeinterventionalSponsorKirby InstituteRan2005 to 2008Enrolled357ConditionsHIV InfectionsArmsEmtricitabine 200mg - Tenofovir 300mg, Abacavir 600mg - Lamivudine 300mg
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 7 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Hila HaskelbergThe Kirby Institute, University of New South Wales, Sydney, Australia.
Nicholas PocockSt. Vincent's Hospital, Sydney, Australia.
Janaki AminThe Kirby Institute, University of New South Wales, Sydney, Australia.
Peter Robert EbelingNorth West Academic Centre, University of Melbourne, Melbourne, Australia.
Sean EmeryThe Kirby Institute, University of New South Wales, Sydney, Australia.
Andrew CarrSt. Vincent's Hospital, Sydney, Australia.
STEAL study investigators
Anthony Allworth
UNSW Sydney · AUSt Vincent's Hospital Sydney · AUUniversity of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTherapy with tenofovir is associated with lower bone mineral density (BMD), higher markers of bone turnover and increased fracture risk in HIV-infected adults. Bone structural parameters generated by hip structural analysis may represent a separate measure of bone strength, but have not been assessed in HIV.

methodsDual-energy X-ray absorptiometry (DXA) scans from 254 HIV-infected adults randomised to simplify their existing dual nucleoside analogue reverse transcriptase inhibitor therapy to coformulated tenofovir-emtricitabine or abacavir-lamivudine were analysed using DXA-derived hip structural analysis software. Hip structural parameters included femoral strength index, section modulus, cross-sectional area, and cross-sectional moment of inertia. We used one-way ANOVA to test the relationship between nucleoside analogue type at baseline and structural parameters, multivariable analysis to assess baseline covariates associated with femoral strength index, and t-tests to compare mean change in structural parameters over 96 weeks between randomised groups.

resultsParticipants taking tenofovir at baseline had lower section modulus (-107.3 mm2, p = 0.001), lower cross-sectional area (-15.01 mm3, p = 0.001), and lower cross-sectional moment of inertia (-2,036.8 mm4, p = 0.007) than those receiving other nucleoside analogues. After adjustment for baseline risk factors, the association remained significant for section modulus (p = 0.008) and cross-sectional area (p = 0.002). Baseline covariates significantly associated with higher femoral strength index were higher spine T-score (p = 0.001), lower body fat mass (p<0.001), lower bone alkaline phosphatase (p = 0.025), and higher osteoprotegerin (p = 0.024). Hip structural parameters did not change significantly over 96 weeks and none was significantly affected by treatment simplification to tenofovir-emtricitabine or abacavir-lamivudine.

conclusionIn this population, tenofovir use was associated with reduced composite indices of bone strength as measured by hip structural analysis, but none of the structural parameters improved significantly over 96 weeks with tenofovir cessation.

trial registrationClinicalTrials.gov NCT00192634.

Indexed as

AbacavirAdenineAnti-HIV AgentsBone DensityDeoxycytidineDideoxynucleosidesDrug CombinationsDrug SubstitutionEmtricitabineFemaleHip JointHIV InfectionsHumansLamivudineMaleOrganophosphonatesAbacavirabacavir, lamivudine drug combinationAdenineAnti-HIV AgentsDeoxycytidineDideoxynucleosidesDrug CombinationsEmtricitabineLamivudineOrganophosphonatesReverse Transcriptase InhibitorsTenofovir

Identifiers

PMID24722774
PMCPMC3983265
OpenAlexW2089327851

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.